Connect your AI

Solid Biosciences Inc. SLDB Earnings yield

Earnings yield at other companies

Sarepta Therapeutics, Inc.SRPT

-4%-4.3pp

BiogenBIIB

5.3%-2.1pp

Neurocrine BiosciencesNBIX

5.1%+2.3pp

InsmedINSM

-3.4%-1.2pp

Dyne Therapeutics, Inc.DYN

-15.1%-5.1pp

Taysha Gene Therapies, Inc.TSHA

-10.1%-4.0pp

Other financials

Income statement

Revenue$2.0M-40.6%

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Total assets$422.9M+23.0%

Cash flow

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation

Market cap$910.66M+135%

Enterprise value$634.23M+223%

P/S112.5×-10.3×

Profitability

Operating margin-1,315.2%-4,060pp

Net margin-1,062.3%-251,151pp

FCF margin-1,247.7%-9,569pp

Returns & leverage

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

net income/market cap=-27.1%

Based on trailing twelve months.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Solid Biosciences Inc.'s earnings yield?: Solid Biosciences Inc. (SLDB) reported earnings yield of -27.1% in Q1 2026.
How has Solid Biosciences Inc.'s earnings yield changed year-over-year?: Solid Biosciences Inc.'s earnings yield increased by 44.4% year-over-year, from -48.7% to -27.1%.
What is the long-term trend for Solid Biosciences Inc.'s earnings yield?: Over 5 years (2020 to 2025), Solid Biosciences Inc.'s earnings yield has grown at a 30.3% compound annual growth rate (CAGR), from -10.6% to -39.7%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.